Introduction
============

Diabetes is a chronic, progressive condition estimated to affect 8% of the US population, the majority of whom are diagnosed with type 2 diabetes (T2D).[@b1-ppa-8-873] If not managed properly, this disease can lead to future complications, including myocardial infarction, stroke, neuropathy, and even death.[@b1-ppa-8-873]--[@b4-ppa-8-873] Research has suggested that lowering glycated hemoglobin (HbA~1c~) to 7% or less is associated with a reduction in the risk of these microvascular and macrovascular complications.[@b2-ppa-8-873]

Basal insulin has been shown to return glycemic levels to the normal range when used properly. "Proper use" entails two major dimensions of patient behavior with respect to treatment: persistence; defined as continuing treatment for the prescribed duration, and adherence; defined as the extent to which a medication is taken at the prescribed intervals, dosing, and frequency.[@b5-ppa-8-873]

Due to the wealth of pharmaceutical claims data, persistence has been well studied among patients with T2D. Indeed, several studies have shown that persistence in basal insulin use has been associated with a greater likelihood of meeting glycemic goals and also greater cost savings.[@b6-ppa-8-873]--[@b8-ppa-8-873] Unfortunately, these studies have not accounted for the adherence dimension of proper use (ie, not just the time on treatment but also using the treatment as prescribed). This is particularly relevant to basal insulins, which must be dosed at regular intervals and at the correct dose in order to achieve normalization of HbA~1c~.

The current study focuses on the dimension of medication adherence among patients with T2D using basal insulin. Assessments of medication adherence with insulin dosing, frequency, and timing have revealed generally suboptimal use of the medication.[@b9-ppa-8-873]--[@b11-ppa-8-873] Adherence can be influenced by a range of complex individual, environmental, and behavioral factors. Researchers have identified an array of predictors of nonadherence,[@b12-ppa-8-873],[@b13-ppa-8-873] including difficulty reading prescription labels,[@b14-ppa-8-873] increased intensity of treatment,[@b14-ppa-8-873] increased symptom burden,[@b15-ppa-8-873] inadequate self-monitoring,[@b16-ppa-8-873] and inadequate disease knowledge.[@b17-ppa-8-873] In addition, the role of personality,[@b18-ppa-8-873] ethnicity,[@b19-ppa-8-873] cost of care,[@b20-ppa-8-873] physician characteristics,[@b21-ppa-8-873] health literacy and education,[@b22-ppa-8-873],[@b23-ppa-8-873] disease and medication beliefs,[@b24-ppa-8-873] and psychopathology have also been explored.[@b25-ppa-8-873] A number of interventions to increase adherence have also been examined in the literature, including those led by a pharmacist,[@b26-ppa-8-873] multidisciplinary teams,[@b27-ppa-8-873] and further utilization of technology.[@b28-ppa-8-873],[@b29-ppa-8-873] These trials note the ongoing challenge of promoting behavior change in the management of chronic disease conditions.[@b30-ppa-8-873]

Although the impact of poor adherence on disease control has been assumed to be significant, few studies have directly assessed the relationship between adherence and key disease-outcome measures, such as HbA~1c~. The Morisky Medication Adherence Scale (MMAS) is a multi-item survey instrument that assesses drug adherence.[@b31-ppa-8-873] A recent article by Krapek et al noted that patient-reported adherence is a predictor of HbA~1c~ using the four-item MMAS.[@b32-ppa-8-873] A broader examination of the effect of adherence on both clinical and nonclinical outcomes has not yet been investigated in this population. Furthermore, the MMAS has since been expanded into an eight-item instrument (MMAS-8) with the potential to provide more precise assessments of adherence.[@b33-ppa-8-873] Since the MMAS was not specifically developed to study insulin dosing, a preliminary aim of the current study was to provide evidence for the validity of the MMAS-8 as a patient-reported instrument in T2D. The main objective of the study was an exploration of the MMAS-8 and its relationship with glycemic control outcomes (HbA~1c~ levels) and other nonclinical outcome measures.

Materials and methods
=====================

Data source
-----------

The 2012 US National Health and Wellness Survey (NHWS) data set was used for this study (n=71,141). The NHWS is a cross-sectional, Internet-based survey administered to a sample of adults (18 years and older) recruited to a panel through opt-in emails, coregistration with other panels, e-newsletter campaigns, and online banner placements. All panelists explicitly agreed to become panel members, registered through unique email addresses, and completed in-depth demographic registration profiles.

Invitations to participate in the NHWS were sent using a random stratified sampling framework to ensure the final sample of NHWS participants was representative of the adult population in the US. Each year, data from the Current Population Survey of the US Census are used to identify the relative proportions of age, sex, and racial/ethnic groups in the US, which are then mimicked during the recruiting of panel members.[@b34-ppa-8-873] Comparisons between the NHWS and other established sources (eg, US Census, National Health Interview Survey, National Health and Nutrition Examination Survey, Medical Expenditure Panel Survey, etc) have been made elsewhere.[@b35-ppa-8-873]--[@b37-ppa-8-873]

Sample
------

Among the 71,141 respondents who completed the 2012 US NHWS, the following inclusion criteria were specified: reported diagnosis of T2D and currently using insulin glargine or insulin detemir. The following exclusion criteria were specified: missing or unknown HbA~1c~ values (as this was the primary outcome) or missing adherence data (as this was the primary predictor).

Measures
--------

### Medication nonadherence

The MMAS-8, a patient-reported instrument with evidence of validity, was used to assess medication nonadherence.[@b33-ppa-8-873]

### HbA~1c~

All respondents who reported a diagnosis of T2D were asked to provide their most recent level of HbA~1c~. Although respondents had the option of selecting "don't know", these respondents were not included in the analyses, as per the aforementioned exclusion criteria.

### Health outcomes

Health status was measured using the Short Form (36) Health Survey, version 2 (SF-36v2); both mental and physical component summary scores were included in the analysis (normed to the US population), along with health state utilities.[@b38-ppa-8-873] Work-related (ie, absenteeism, presenteeism, and overall work impairment) and activity-related impairment were assessed using the general health version of the Work Productivity and Activity Impairment questionnaire (WPAI-GH).[@b39-ppa-8-873] The total number of physician visits, emergency room (ER) visits, and hospitalizations in the past 6 months were also reported.

### Sociodemographics

Age, race/ethnicity, sex, marital status (married/living with partner versus all else), education (less than college graduate versus college graduate or more), and annual household income (\<\$25,000, \$25,000 to \<\$50,000, \$50,000 to \<\$75,000, ≥\$75,000, declined to answer) were assessed.

### Health history

Each respondent was asked to provide information on their height and weight, which was then converted to a level of body mass index (BMI) and categorized according to Centers for Disease Control and Prevention criteria (ie, underweight, normal weight, overweight, obese, and declined to answer). The Charlson Comorbidity Index (CCI) was used to assess overall comorbidity burden.[@b40-ppa-8-873] The CCI is calculated by weighting the presence of multiple conditions, including human immunodeficiency syndrome/acquired immunodeficiency syndrome, metastatic tumor, lymphoma, and others. The greater the total index score, the greater the comorbid burden on the patient.

Statistical analysis
--------------------

Classical test theory analyses were used to document the evidence of reliability and validity of the MMAS-8. These analyses included internal consistency using Cronbach's *α*, inter-item correlations, item-to-total correlations, and exploratory factor analysis (using principal axis factoring with a varimax rotation). Item response theory (IRT) analyses were also conducted to further provide psychometric evidence of the MMAS-8 and its individual items. Specifically, we compared the fit of a one-parameter (which assumes equivalent discrimination among items) versus a two-parameter (which allows discrimination to vary) model and examined item characteristic curves, item information curves, and test information curves.

Multiple regression models were then conducted to examine the relationship between nonadherence and HbA~1c~, controlling for relevant sociodemographic and health history variables. These covariates included age, sex, race/ethnicity, marital status, education, annual household income, employment, insurance, BMI category, alcohol use, smoking behavior, exercise behavior, and the CCI. Higher-order trends (ie, quadratic, cubic) were also examined to determine the functional relationship between nonadherence and HbA~1c~. A higher-order trend was only examined if the immediate lower order was significant (eg, only if a linear relationship was significant would a quadratic relationship be tested; only if a quadratic relationship was significant would a cubic relationship be tested, etc).

Additional regression models were then conducted to assess the relationship between nonadherence and other health outcomes, controlling for the same sociodemographic and health history variables previously noted. Multiple regression (ie, ordinary least squares) models were used for health status variables, while generalized linear models (specifying a negative binomial distribution and a log-link function) were used for work-productivity and resource-use variables, because of pronounced skew. Statistical significance was set a priori at *P*\<0.05.

Results
=======

A total of 1,198 respondents reported a diagnosis of T2D, were currently using basal insulin, and reported both their HbA~1c~ and level of nonadherence; 61.44% of these respondents were male, and the mean age was 60.65 years (standard deviation 10.74; see [Table 1](#t1-ppa-8-873){ref-type="table"}). Engagement in nonadherent behaviors (the individual items of the MMAS-8) varied considerably, from stopping medication when feeling worse (5.76%) to having difficulty remembering to take all medications (32.22%) (see [Table 2](#t2-ppa-8-873){ref-type="table"}). Internal consistency of the MMAS-8 was adequate (Cronbach's *α*=0.68), although it would have been improved upon removal of the "Did you take your medicine yesterday?" item (Cronbach's *α*=0.70 if removed). Indeed, this particular item was not significantly related to the total score (*r*=0.05).

Exploratory factor analysis results suggested that one factor be retained (eigenvalue =1.80). Given this unidimensionality, IRT analyses were then undertaken, and revealed that a two-parameter model was a significantly better fit than a one-parameter model based on both a lower Akaike information criterion (AIC) (6844.79 versus 6965.94) and a significant likelihood-ratio test (*χ*^2^\[7\]=135.15, *P*\<0.05).

Using a two-parameter model, item difficulty and discrimination were reported for each item (see [Table 3](#t3-ppa-8-873){ref-type="table"}). Items with the strongest discrimination included any day's medicine not taken, sometimes forgetting, and having difficulty remembering to take all medications (2.81, 2.47, and 2.21, respectively) (see [Table 3](#t3-ppa-8-873){ref-type="table"}). Most other items exhibited solid psychometric properties (eg, discrimination \>1.40); however, "Did you take your medicine yesterday?" provided little information (discrimination =0.20, information =0.02). The item characteristic curves are shown in [Figures 1](#f1-ppa-8-873){ref-type="fig"} and [2](#f2-ppa-8-873){ref-type="fig"}.

Individual items of the MMAS-8 were then examined with respect to their information (see [Figure 3](#f3-ppa-8-873){ref-type="fig"}). Greater information indicates greater precision in measuring nonadherence at that level of nonadherence. For example, any days when medicine not taken, and sometimes forgetting, had the greatest level of information (as also shown in [Table 3](#t3-ppa-8-873){ref-type="table"}), and this level of information was highest between the mean (θ=0) and two standard deviations above the mean (θ=2). Indeed, the information curves for most items generally peaked between zero and two standard deviations above the mean, with ever stopping because of feeling worse, and sometimes stopping because of feeling that the condition is under control, both exhibiting the greatest level of information, slightly above two standard deviations above the mean.

The test information curve (ie, the sum of the individual item information curves) demonstrated that information is generally low until the mean (θ=0), peaks between zero and two standard deviations above the mean, and then gradually tails off. As information is a measure of the precision of the instrument, it can be said that the MMAS-8 is the most precise at measuring nonadherence when the level of nonadherence is above the mean, particularly between zero and two standard deviations.

Given the evidence of the MMAS-8 as an instrument that is reliably capturing a unidimensional construct of nonadherence, analyses were then conducted to examine the relationship between nonadherence and HbA~1c~. A significant relationship between these variables was uncovered, whereby each point increase in the level of nonadherence was associated with a 0.21 increase in HbA~1c~ (*B*=0.212, *P*\<0.05). A modest quadratic trend was also observed (*B*=0.026, *P*\<0.05) indicating that HbA~1c~ levels out and does not continue improving with increasing adherence; therefore, the benefit to HbA~1c~ of high adherence may be limited. No cubic was observed, and as a result no further trends were examined. The regression lines are graphically displayed in [Figure 4](#f4-ppa-8-873){ref-type="fig"}.

Nonadherence was also used as a predictor of nonclinical health outcomes, including health status (SF-36v2), work productivity and activity impairment (WPAI-GH), and health care-resource use. With respect to health status, poorer adherence was associated with significantly worse summary and domain scores, with the exception of the physical component summary score (see [Table 4](#t4-ppa-8-873){ref-type="table"}). Each point increase in nonadherence was associated with a decrease of between 0.46 (bodily pain) and 1.41 (mental component summary scores), holding sociodemographics and health history variables constant. Health utilities decreased 0.011 points for every point increase in nonadherence. Given the size of these effects, an adherence change of 2--3 points would yield a clinically meaningful change in health status (defined as 3 points on a norm-based summary/domain score and 0.03 points for health utilities). Nonadherence was not associated with any significant change in work-productivity metrics (see [Table 5](#t5-ppa-8-873){ref-type="table"}). However, nonadherence was associated with a modest increase (6.4%) in activity-related impairment (*B*=0.06, rate ratio 1.06; *P*\<0.05). Nonadherence was also associated with a significant increase in the number of resource-use events. Specifically, each point of nonadherence was associated with a 4.6%, 20.4%, and 20.9% increase in the number of physician visits, ER visits, and hospitalizations, respectively (physician visits, *B*=0.05, rate ratio 1.05, *P*\<0.05; ER visits, *B*=0.19, rate ratio 1.20, *P*\<0.05; hospitalizations, *B*=0.19, rate ratio 1.21, *P*\<0.05).

Discussion
==========

Patient adherence to medication continues to be a major challenge in the long-term management of T2D. Yet there is a lack of research regarding the relationship between patient nonadherence and disease outcomes, and the field continues to struggle with measurement issues of adherence itself. Patient-reported assessments of adherence are certainly among the easiest to administer, though they have been criticized due to their potential for inaccuracy. The current study sought to provide some evidence that a patient-reported instrument, the MMAS-8, can be used reliably in this patient population.

Indeed, the results suggest the MMAS-8 was measuring a single construct and was generally internally consistent (though, taking medication yesterday, was not a particularly helpful item in patients with T2D using basal insulin). Further, the IRT analyses suggest that most items perform well (again, with the exception of taking medication yesterday), and the MMAS-8 was most reliable (ie, provided the most information about a patient's level of adherence) when there was a moderate-to-high degree of nonadherence. Given the suboptimal rates of adherence observed in the literature[@b9-ppa-8-873] and replicated in this study (eg, nearly 20% report sometimes forgetting to take their medication and approximately 30% feeling hassled by their regimen and having difficulty remembering to take it), this focused precision of the MMAS-8 is far from problematic in this population. Nevertheless, future studies should be cognizant of this when exploring insulin subgroups likely to be adherent. Although there may be many alternative forms of assessing adherence in a T2D sample, the MMAS-8 appears to provide a psychometrically valid way to assess adherence in this population.

Our results also suggest that greater nonadherence was associated with worse health outcomes. Of particular note, each point increase in nonadherence was associated with a 0.21 increase in HbA~1c~, which was generally comparable to what has been observed in past studies.[@b32-ppa-8-873] To our knowledge, the current study was the first of its kind to examine nonlinear relationships between adherence and HbA~1c~. Indeed, a slight quadratic trend was observed, which indicates this effect is weaker at high levels of adherence. When focusing on populations with a high level of adherence, the impact of adherence on HbA~1c~ is less dramatic. In other words, there is only so much HbA~1c~ benefit that can be achieved with adherence to basal insulin, as there is a ceiling effect based on the effectiveness of the medication itself.

We also found significant associations between nonadherence and health status. A 2- to 3-point increase in the MMAS-8 was associated with clinically relevant effects for several summary and domain scores, particularly mental health-related scores. However, this finding raises the question of the causality of this effect. There may be underlying mental health issues that cause nonadherence, rather than nonadherence causing poorer mental health (though both may occur). Although no effect was observed in terms of work productivity (and only a modest one in terms of activity impairment), sizable effects were observed with respect to health care-resource use. In particular, over 20% more hospitalizations and ER visits were reported for each additional 1-point increase in nonadherence. Although nonadherence was also associated with significantly more physician visits, this effect was far more modest. The implication of these results may be that poor adherence may lead to acute events that require immediate medical attention. However, additional research would be necessary to replicate these effects outside a cross-sectional design.

In sum, this study provides evidence that adherence rates are high among patients with T2D using basal insulin, and the MMAS-8 is a reliable and valid tool to assess adherence. Further, examining adherence with this tool has shown that HbA~1c~ increases concomitantly with nonadherence, as do poorer health status and health care-resource use. Innovative interventions designed to improve adherence in this population may result in real-world clinical benefits and cost savings. For example, evaluations of interventions that include reminders (perhaps by involving caregivers), increase mindfulness of treatment behaviors or clarify treatment regimens appear to be lines of future inquiry with the potential to produce the most positive impact. These findings also have implications from a purely clinical perspective. Although the MMAS-8 was developed for the purposes of research, it may help those in clinical practice to determine potentially nonadherent patients (eg, patients who report being hassled or bothered with the regimen). This could offer clinicians the opportunity to intervene early, stressing the importance of proper medication use with their patients, and in certain situations could lead to altering the treatment regimen to one where the patient is more likely to adhere. Such clinical intervention may help to mitigate the deleterious effects of nonadherence. Additionally, future treatments that increase the convenience of the regimen may also result in a clinical benefit due to improved adherence.

Limitations
-----------

Several limitations of this research should be noted. All data from the NHWS were patient-reported, and objective confirmation of patient information was unavailable. Naturally, we should emphasize that this includes HbA~1c~, which was entirely self-reported. Past research has suggested a moderately sized correlation (*r*=0.43) between self-reported HbA~1c~ and actual HbA~1c~, though far from a perfect one.[@b41-ppa-8-873] Assuming no systematic bias in these HbA~1c~-recall errors, this additional measurement error would serve to weaken our observed effect, making these findings conservative. Future research should rely on objective measures of HbA~1c~ to replicate these relationships. Additionally, because the NHWS is cross-sectional, a causal relationship between nonadherence and HbA~1c~ levels and other health outcomes can only be speculated from the available data. Indeed, it is possible that the relationship between nonadherence and HbA~1c~ could be explained at least partially by variables that cause both nonadherence and glucose intolerance (ie, third variables). The NHWS sample overall is identical to that of the US adult population overall with respect to age, sex, and race/ethnicity. However, there may be other variables that differ between the NHWS and the adult population, which could influence the strength and direction of the associations observed here.
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![Adjusted levels of HbA~1c~ as a function of nonadherence.\
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**Abbreviations:** MMAS-8, eight-item Morisky Medication Adherence Scale; HbA~1c~, glycated hemoglobin.](ppa-8-873Fig4){#f4-ppa-8-873}

###### 

Demographics and diabetes characteristics of the study sample (n=1,198)

                                              n
  ------------------------------------------- --------------
  Age (mean ± SD)                             60.65±10.74
  Male                                        736 (61.44%)
  Race/ethnicity                              
   Non-Hispanic White                         938 (78.30%)
   Non-Hispanic Black                         122 (10.18%)
   Hispanic                                   80 (6.68%)
   Other race/ethnicity                       58 (4.84%)
  University education or higher              423 (35.31%)
  Annual household income                     
   \<\$25K                                    293 (24.46%)
   \$25K to \<\$50K                           335 (27.96%)
   \$50K to \<\$75K                           243 (20.28%)
   \$75K or more                              253 (21.12%)
   Decline to answer                          74 (6.18%)
   Employed                                   375 (31.30%)
  Body mass index (BMI) category              
   Underweight                                1 (0.08%)
   Normal weight                              64 (5.34%)
   Overweight                                 265 (22.12%)
   Obese                                      843 (70.37%)
   Decline to provide weight                  25 (2.09%)
  Charlson comorbidity index (mean ± SD)      1.92±1.44
  Years diagnosed with diabetes (mean ± SD)   15.83±9.30
  HbA~1c~ (mean ± SD)                         7.42±1.50

**Abbreviation:** SD, standard deviation.

###### 

Frequency of endorsement and internal consistency of the eight-item Morisky Medication Adherence Scale (MMAS-8) items

  MMAS-8 items                                                                                                                     \% endorsed   *r* with total   *α* if removed[\*](#tfn2-ppa-8-873){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------------------------------------- ------------- ---------------- ----------------------------------------------------------
  Do you sometimes forget to take your pills?                                                                                      19.95         0.494            0.612
  Thinking over the past 2 weeks, were there any days when you did not take your medicine?                                         14.77         0.525            0.607
  Have you ever cut back or stopped taking your medication without telling your doctor, because you felt worse when you took it?   5.76          0.308            0.662
  When you travel or leave home, do you sometimes forget to bring along your medication?                                           12.35         0.402            0.639
  Did you take your medicine yesterday? (reverse-coded)                                                                            6.26          0.049            0.701
  When you feel like your condition is under control, do you sometimes stop taking your medicine?                                  6.59          0.274            0.667
  Do you ever feel hassled about sticking to your treatment plan?                                                                  28.80         0.381            0.648
  Do you have difficulty remembering to take all your medications?                                                                 32.22         0.487            0.614

**Note:**

Represents the Cronbach's α of the remaining MMAS-8 if the given item was removed.

###### 

Item-level properties of the eight-item Morisky Medication Adherence Scale (MMAS-8)

  MMAS-8 items                                                                                                                     Difficulty   Discrimination   Information
  -------------------------------------------------------------------------------------------------------------------------------- ------------ ---------------- -------------
  Do you sometimes forget to take your pills?                                                                                      1.03         2.47             2.47
  Thinking over the past 2 weeks, were there any days when you did not take your medicine?                                         1.24         2.81             2.81
  Have you ever cut back or stopped taking your medication without telling your doctor, because you felt worse when you took it?   2.52         1.43             1.27
  When you travel or leave home, do you sometimes forget to bring along your medication?                                           1.72         1.59             1.55
  Did you take your medicine yesterday? (reverse-coded)                                                                            13.52        0.20             0.02
  When you feel like your condition is under control, do you sometimes stop taking your medicine?                                  2.75         1.16             0.94
  Do you ever feel hassled about sticking to your treatment plan?                                                                  0.95         1.22             1.19
  Do you have difficulty remembering to take all your medications?                                                                 0.58         2.21             2.21

**Notes:** Difficulty represents the standardized level of adherence that is associated with an equal probability of endorsing or not endorsing a given item. Discrimination represents the slope of the item curve when the probability of endorsing the item is 0.50. Information represents the inverse of the item variance at each level of standardized adherence.

###### 

Summary table of adjusted relationship between non-adherence and health status summary and domain scores (Short Form \[36\] Health Survey, version 2)

  Variable                     B        SE B    *t*      *P*-value
  ---------------------------- -------- ------- -------- -----------
  Mental component summary     −1.414   0.202   −6.980   \<0.0001
  Physical component summary   −0.101   0.176   −0.570   0.5657
  Health utilities             −0.011   0.002   −4.870   \<0.0001
  Bodily pain                  −0.461   0.195   −2.370   0.0181
  General health               −0.559   0.178   −3.140   0.0018
  Vitality                     −0.835   0.184   −4.550   \<0.0001
  Social functioning           −1.011   0.201   −5.030   \<0.0001
  Mental health                −1.420   0.207   −6.860   \<0.0001
  Emotional role limitations   −0.970   0.230   −4.210   \<0.0001
  Physical role limitations    −0.750   0.199   −3.770   0.0002
  Physical functioning         −0.083   0.190   −0.440   0.6617

**Abbreviation:** B, unstandardized regression estimate; SE, standard error.

###### 

Summary table of adjusted relationship between nonadherence and work productivity and activity impairment scores

                               B       Rate ratio   SE B    95% LCL   95% UCL   *χ*^2^   *P*-value
  ---------------------------- ------- ------------ ------- --------- --------- -------- -----------
  Absenteeism, %               0.036   1.037        0.259   −0.471    0.543     0.020    0.888
  Presenteeism, %              0.060   1.062        0.088   −0.113    0.233     0.470    0.495
  Overall work impairment, %   0.055   1.056        0.087   −0.115    0.224     0.400    0.525
  Activity impairment, %       0.062   1.064        0.026   0.011     0.113     5.600    0.018
  Number of physician visits   0.045   1.046        0.015   0.015     0.075     8.450    0.004
  Number of ER visits          0.185   1.204        0.044   0.100     0.271     17.890   \<0.0001
  Number of hospitalizations   0.190   1.209        0.053   0.087     0.293     13.060   \<0.0001

**Abbreviations:** SE, standard error; ER, emergency room; B, unstandardized regression estimate; LCL, lower confidence level; UCL, upper confidence level.
